DIMENSION

Hiring AI/ML talent at @achira_ai to build world models for molecules We're looking for scientists and research engineers who will join Achira's technical staff to join its mission to build microscopic world models. As large scale AI models have matured and revolutionized our ability to intervene on the digital world, we are increasingly racing towards physical AI as the next frontier. Achira builds foundation simulation models that will explictly model the microcosm on an atomistic level with a goal to deeply impact virtual chemistry in service of drug discovery and is marrying the best of deep learning/generative AI with physics, statistical mechanics, and quantum chemistry. If you're up for the challenge to build at the frontier, come join us. achira.ai/careers/

x.com/i/article/2047…

x.com/i/article/2047…

x.com/i/article/2047…

For decades, drug discovery has shifted away from nature and toward biology-first approaches. @viswacolluru believes that shift was a catastrophic mistake. His company, Enveda (@lifeschemistry), has raised over $500 million to build a “search engine for nature’s chemistry.” In our conversation, we explore: • Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) • How Enveda built a system to decode unknown molecules in nature • The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work • Why old ideas, from immunotherapy to natural products, often hold the most latent potential • How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million • Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis • Why first-in-class medicines capture the vast majority of returns in pharma • What competitive table tennis taught him about building companies Thank you to the partners who make this possible @brexHQ: The intelligent finance platform: brex.com/mario @ahrefs Brand Radar: Find your brand in AI results: ahrefs.com/generalist @withpersona: Trusted identity verification for any use case: withpersona.com/generalist (00:00) Introduction to Viswa Colluru (07:06) Early pull toward technology (14:24) Studying Biotechnology (24:23) Innovation vs. novelty (32:05) Joining Recursion (40:42) What launched Enveda (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation

.@_DimensionCap has led, alongside DST Global and Hillhouse, $787M of new financings into Earendil Labs. The company uses cutting edge AI to redesign every joint of the discovery, design, manufacturing, and development process for new medicines, and is pioneering some of the most inventive research we’ve seen across the US and China. In terms of novel, orthogonal research: I’d describe this as the Deepseek of biotech. The company has multiple partnered and wholly owned assets entering or already in the clinic, and is building a burgeoning pipeline across I&I and onc .. pushing the boundaries of multispecific, multivalent, and next gen modalities. The team has publicly commented on pipeline, platform, and research partnerships with Sanofi, Wuxi and NVidia. I have to imagine: more to come. Finally, the company is led by famed UIUC/Tsinghua computer science professor, Jian Peng, and the original inventor of the class of PD-1/VEGF bispecifics, Zhenping Zhu. prnewswire.com/news-releases/…

x.com/i/article/2043…

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

Join us in recognizing Delta's Rising Investors of 2026! 🎉 Congrats to the investors our community nominated as truly exceptional at the early stage. Angels, emerging fund managers, and established names alike, recognized for their track records, the depth of their writing, and their presence in the technical community. These are the people who cut through the noise, back the right companies early, and show up as real partners to the founders they work with. deltainstitutes.org/rising-investo…

Join us in recognizing Delta's Rising Investors of 2026! 🎉 Congrats to the investors our community nominated as truly exceptional at the early stage. Angels, emerging fund managers, and established names alike, recognized for their track records, the depth of their writing, and their presence in the technical community. These are the people who cut through the noise, back the right companies early, and show up as real partners to the founders they work with. deltainstitutes.org/rising-investo…

x.com/i/article/2038…

Exclusive: Enveda's first clinical readout shows early promise for its lead eczema drug I talked with @viswacolluru on the ENV-294 data and next steps, including a Phase 2a readout expected in 2H26: endpoints.news/envedas-first-…

We gave AI agents varying freedom to optimize models for protein thermostability prediction. They beat a 15x larger reference model, matched Bayesian optimization. And we learned a hybrid approach may work even better. Blog: research.dimensioncap.com/p/the-melting-…